PMID- 29156517
OWN - NLM
STAT- MEDLINE
DCOM- 20180807
LR  - 20180807
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 97
DP  - 2018 Jan
TI  - MiR-504 inhibits cell proliferation and invasion by targeting LOXL2 in non small 
      cell lung cancer.
PG  - 1289-1295
LID - S0753-3322(17)34520-1 [pii]
LID - 10.1016/j.biopha.2017.11.005 [doi]
AB  - BACKGROUND: MicroRNAs (miRNAs) play crucial roles in tumor initiation and 
      development. The aim of the study was to explore the clinicopathological role and 
      functional effects of miR-504 in non small cell lung cancer (NSCLC). METHODS: 
      Quantitative reverse transcription polymerase chain reaction (QRT-PCR) was 
      applied to detect the expression of miR-504 in 55 cases of NSCLC tissues and 
      matched adjacent normal tissues in NSCLC patients. MTT, colony formation and 
      transwell invasion assays were performed to evaluate the effects of miR-504 on 
      cell proliferation and invasion, respectively. Dual luciferase reporter assay was 
      used to verify that LOXL2 was a direct target of miR-504. QRT-PCR and western 
      blot analysis were performed to analyze mRNA and protein expression. RESULTS: In 
      the study, we demonstrated that miR-504 was notably downregulated in NSCLC 
      tissues compared with adjacent normal tissues. Lower miR-504 expression 
      positively correlated with lymph node metastasis and advanced TNM stage in 
      patients. Furthermore, upregulation of miR-504 significantly inhibited cell 
      proliferation, cell invasion and EMT process of NSCLC. QRT-PCR, western blot and 
      luciferase reporter assays confirmed that miR-504 could bind to LOXL2 3'UTR 
      region and regulate its expression. Moreover, ectopic expression of LOXL2 could 
      rescue the inhibiting effects on cell proliferation and invasion induced by 
      miR-504 in NSCLC cells. CONCLUSIONS: Our results indicated that miR-504 
      functioned as a tumor suppressor in NSCLC and may serve as a target of NSCLC 
      treatment.
CI  - Copyright (c) 2017 Elsevier Masson SAS. All rights reserved.
FAU - Ye, Ming-Fan
AU  - Ye MF
AD  - Department of Thoracic Surgery, FuJian Provincial Hospital, Fuzhou 350001, 
      People's Republic of China. Electronic address: yemfymf1@126.com.
FAU - Zhang, Ji-Guang
AU  - Zhang JG
AD  - Department of Thoracic Surgery, FuJian Provincial Hospital, Fuzhou 350001, 
      People's Republic of China. Electronic address: zhangji1g@21cn.com.
FAU - Guo, Tian-Xing
AU  - Guo TX
AD  - Department of Thoracic Surgery, FuJian Provincial Hospital, Fuzhou 350001, 
      People's Republic of China. Electronic address: guotianxi1@21cn.com.
FAU - Pan, Xiao-Jie
AU  - Pan XJ
AD  - Department of Thoracic Surgery, FuJian Provincial Hospital, Fuzhou 350001, 
      People's Republic of China. Electronic address: panxiaojiej@126.com.
LA  - eng
PT  - Journal Article
DEP - 20171214
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (MIRN504 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Messenger)
RN  - EC 1.4.- (Amino Acid Oxidoreductases)
RN  - EC 1.4.3.- (LOXL2 protein, human)
SB  - IM
MH  - Amino Acid Oxidoreductases/*genetics
MH  - Blotting, Western
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/pathology
MH  - Cell Proliferation/genetics
MH  - Down-Regulation
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*genetics/pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - Neoplasm Invasiveness/genetics
MH  - RNA, Messenger/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Up-Regulation/genetics
OTO - NOTNLM
OT  - Epithelial-mesenchymal transition
OT  - LOXL2
OT  - MiR-504
OT  - Non small cell lung cancer
EDAT- 2017/11/22 06:00
MHDA- 2018/08/08 06:00
CRDT- 2017/11/22 06:00
PHST- 2017/09/02 00:00 [received]
PHST- 2017/10/26 00:00 [revised]
PHST- 2017/11/03 00:00 [accepted]
PHST- 2017/11/22 06:00 [pubmed]
PHST- 2018/08/08 06:00 [medline]
PHST- 2017/11/22 06:00 [entrez]
AID - S0753-3322(17)34520-1 [pii]
AID - 10.1016/j.biopha.2017.11.005 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2018 Jan;97:1289-1295. doi: 10.1016/j.biopha.2017.11.005. 
      Epub 2017 Dec 14.